PPARG and Parkinson disease: Several preclinical trials have used PPARγ agonists in different PD animal models, attempting to demonstrate their positive counter-effects on ROS generation, mitochondrial dysfunction, neuroinflammation, neurogenesis, and the loss of dopaminergic neurons.